Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 421,524
  • Shares Outstanding, K 34,354
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,920 K
  • EBIT $ -51 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.07

Options Overview Details

View History
  • Implied Volatility 353.89% (+28.21%)
  • Historical Volatility 60.86%
  • IV Percentile 93%
  • IV Rank 74.61%
  • IV High 445.82% on 03/03/26
  • IV Low 83.70% on 09/03/25
  • Expected Move (DTE 9) 1.02 (8.31%)
  • Put/Call Vol Ratio 10.00
  • Today's Volume 22
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 83
  • Open Int (30-Day) 78
  • Expected Range 11.25 to 13.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.29
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.85 +24.57%
on 02/17/26
13.39 -8.40%
on 03/09/26
+0.57 (+4.87%)
since 02/10/26
3-Month
9.85 +24.57%
on 02/17/26
14.39 -14.73%
on 12/31/25
-0.54 (-4.22%)
since 12/10/25
52-Week
9.85 +24.57%
on 02/17/26
17.15 -28.45%
on 06/10/25
unch (unch)
since 03/10/25

Most Recent Stories

More News
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in...

HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

- The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Inc. Announces Proposed Public Offering

HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has...

BNTC : 12.27 (-2.23%)
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...

BNTC : 12.27 (-2.23%)

Business Summary

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B,...

See More

Key Turning Points

3rd Resistance Point 14.15
2nd Resistance Point 13.67
1st Resistance Point 12.97
Last Price 12.27
1st Support Level 11.80
2nd Support Level 11.32
3rd Support Level 10.62

See More

52-Week High 17.15
Fibonacci 61.8% 14.36
Fibonacci 50% 13.50
Fibonacci 38.2% 12.64
Last Price 12.27
52-Week Low 9.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar